Class action lawsuit filed against Biogen Inc. (BIIB) to seek compensation for investors

NEW YORK, 25 June 2024 /PRNewswire/ — The Gross Law Firm issues the following notice to shareholders of Biogen Inc. (NASDAQ: BIIB).

Shareholders who purchased shares of BIIB during the specified period are encouraged to contact the firm regarding a possible appointment as lead plaintiff. Appointment as lead plaintiff is not required to participate in any recovery.

CONTACT US HERE:

Biogen Loss Submission Form

SCHOOL LESSON: February 3, 2022 To February 13, 2024

ACCUSATIONS: The complaint claims that during the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Biogen overstated its efforts to improve its transparency, corporate governance and compliance controls and procedures and the effectiveness of those controls and procedures; (ii) Biogen accordingly maintained inadequate compliance controls and procedures in connection with its foreign operations; (iii) Biogen and/or its employees engaged in unlawful or otherwise improper conduct in several countries; (iv) the foregoing placed the Company at increased risk of governmental and/or regulatory scrutiny and enforcement actions, as well as significant legal, financial and reputational damages; (v) Biogen overstated the strength of its Alzheimer’s-related product portfolio, including its joint efforts and success with pharmaceutical company Eisai in launching and making Leqembi available; (vi) Biogen also downplayed the negative impact of the Reata acquisition on its non-GAAP diluted earnings per share in fiscal 2023; (vii) all of the foregoing would likely have a material adverse effect on Biogen’s 2023 results; and (viii) as a result, the Company’s public statements were materially false and misleading at all relevant times.

DEADLINE: July 22, 2024 Shareholders should not hesitate to sign up for this class action lawsuit. Register your information here: https://securitiesclasslaw.com/securities/biogen-loss-submission-form/?id=87117&from=4

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of BIIB within the time period outlined above, you will be enrolled in a portfolio monitoring software that will provide you with status updates throughout the lifecycle of the case. The deadline to serve as lead plaintiff is July 22, 2024Participation in this case is free of charge and non-binding for you.

WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm. Our mission is to protect the rights of all investors who have suffered fraud. Fraudand illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in corporate citizenship. The firm seeks compensation on behalf of investors who have suffered losses when a company’s false and/or misleading statements or omission of material information have resulted in the artificial inflating of the company’s stock price. Attorney Advertising. Past results do not guarantee similar results.

CONTACT:
The law firm Gross
15 West 38th Street, 12th floor
New York, NY10018
E-mail: (email protected)
Phone: (646) 453-8903

Never miss a story from Gross Law Firm again.